The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 04, 2012

Filed:

May. 08, 2009
Applicants:

Jijie Gu, Shewsbury, MA (US);

Chung-ming Hsieh, Newton, MA (US);

Zhen Wu, Framingham, MA (US);

Enrico L. Digiammarino, Lindenhurst, IL (US);

Feng Luo, Arlington Heights, IL (US);

Gerard B. Fox, Barrington Hills, IL (US);

John E. Harlan, Lake Zurich, IL (US);

Martin Schmidt, Bensheim, DE;

Ralf Loebbert, Speyer, DE;

Reinhold Mueller, Schifferstadt, DE;

Ulrich Ebert, Mannheim, DE;

Volker Nimmrich, Heidelberg, DE;

Inventors:

Jijie Gu, Shewsbury, MA (US);

Chung-Ming Hsieh, Newton, MA (US);

Zhen Wu, Framingham, MA (US);

Enrico L. DiGiammarino, Lindenhurst, IL (US);

Feng Luo, Arlington Heights, IL (US);

Gerard B. Fox, Barrington Hills, IL (US);

John E. Harlan, Lake Zurich, IL (US);

Martin Schmidt, Bensheim, DE;

Ralf Loebbert, Speyer, DE;

Reinhold Mueller, Schifferstadt, DE;

Ulrich Ebert, Mannheim, DE;

Volker Nimmrich, Heidelberg, DE;

Assignees:

Abbott Laboratories, Abbott Park, IL (US);

Abbott GmbH & Co. KG, Wiesbaden-Delkenheim, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07H 21/04 (2006.01); C07K 16/00 (2006.01); A61P 25/28 (2006.01); C12N 15/63 (2006.01); C12N 5/10 (2006.01); C12P 21/02 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example misfolded proteins like amyloid β and advanced glycation-end-products.


Find Patent Forward Citations

Loading…